See more : RF Capital Group Inc. (GMPXF) Income Statement Analysis – Financial Results
Complete financial analysis of Zymeworks Inc. (ZYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymeworks Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- P10, Inc. (PX) Income Statement Analysis – Financial Results
- aifinyo AG (EBE.DE) Income Statement Analysis – Financial Results
- Vmoto Limited (VMT.AX) Income Statement Analysis – Financial Results
- Pili International Multimedia Co.,Ltd. (8450.TWO) Income Statement Analysis – Financial Results
- AMPAK Technology Inc. (6546.TWO) Income Statement Analysis – Financial Results
Zymeworks Inc. (ZYME)
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.01M | 412.48M | 26.68M | 38.95M | 29.54M | 53.02M | 51.76M | 11.01M | 9.66M | 1.67M |
| Cost of Revenue | 142.99M | 208.70M | 199.54M | 170.90M | 117.10M | 56.93M | 41.14M | 35.55M | 24.40M | 10.47M |
| Gross Profit | -66.98M | 203.78M | -172.86M | -131.95M | -87.55M | -3.91M | 10.62M | -24.54M | -14.74M | -8.80M |
| Gross Profit Ratio | -88.11% | 49.40% | -647.90% | -338.75% | -296.34% | -7.37% | 20.51% | -222.93% | -152.62% | -527.13% |
| Research & Development | 143.62M | 208.60M | 199.75M | 168.53M | 115.90M | 56.68M | 41.75M | 36.82M | 24.65M | 12.62M |
| General & Administrative | 70.45M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Selling & Marketing | -46.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 70.40M | 73.36M | 42.56M | 57.89M | 64.18M | 29.46M | 18.55M | 12.55M | 5.22M | 3.95M |
| Other Expenses | -142.94M | 4.71M | 3.27M | 7.35M | 5.28M | -1.26M | -964.00K | -1.27M | -251.00K | -2.15M |
| Operating Expenses | 71.08M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Cost & Expenses | 214.07M | 281.95M | 242.31M | 226.42M | 180.08M | 86.15M | 59.22M | 48.11M | 29.62M | 14.42M |
| Interest Income | 19.71M | 3.60M | 1.97M | 5.70M | 6.02M | 2.64M | 743.00K | 308.00K | 324.00K | 116.00K |
| Interest Expense | 0.00 | 3.60M | 0.00 | 0.00 | 0.00 | 166.00K | 892.00K | 950.00K | 18.00K | 9.00K |
| Depreciation & Amortization | 17.31M | 12.00M | 9.58M | 10.28M | 7.33M | 3.63M | 2.74M | 1.03M | 494.00K | 412.00K |
| EBITDA | -129.96M | 147.24M | -206.09M | -177.17M | -143.19M | -30.76M | -6.08M | -36.26M | -18.62M | -12.34M |
| EBITDA Ratio | -170.97% | 31.64% | -808.22% | -481.29% | -506.92% | -62.48% | -11.45% | -329.37% | -198.16% | -749.28% |
| Operating Income | -138.05M | 130.53M | -215.63M | -187.47M | -151.30M | -33.13M | -9.00M | -37.86M | -19.96M | -12.75M |
| Operating Income Ratio | -181.62% | 31.64% | -808.22% | -481.29% | -512.12% | -62.48% | -17.38% | -343.94% | -206.63% | -763.35% |
| Total Other Income/Expenses | 18.81M | 4.71M | 3.27M | 7.35M | 5.28M | -1.02M | -964.00K | -1.02M | 824.00K | -194.00K |
| Income Before Tax | -119.24M | 135.23M | -212.36M | -180.12M | -146.02M | -34.39M | -9.96M | -38.88M | -19.14M | -12.94M |
| Income Before Tax Ratio | -156.87% | 32.79% | -795.95% | -462.43% | -494.24% | -64.85% | -19.25% | -353.20% | -198.10% | -774.97% |
| Income Tax Expense | -568.00K | 10.89M | -516.00K | 429.00K | -582.00K | 2.17M | 444.00K | -5.08M | 34.00K | -284.00K |
| Net Income | -118.67M | 124.34M | -211.84M | -180.55M | -145.44M | -36.56M | -10.41M | -33.81M | -19.17M | -12.94M |
| Net Income Ratio | -156.13% | 30.14% | -794.01% | -463.54% | -492.27% | -68.95% | -20.10% | -307.10% | -198.45% | -774.97% |
| EPS | -1.72 | 1.91 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| EPS Diluted | -1.72 | 1.90 | -4.06 | -3.58 | -3.83 | -1.26 | -0.49 | -1.72 | -0.97 | -0.65 |
| Weighted Avg Shares Out | 68.86M | 65.19M | 52.13M | 50.38M | 37.97M | 29.01M | 21.25M | 19.70M | 19.84M | 19.84M |
| Weighted Avg Shares Out (Dil) | 68.86M | 65.25M | 52.13M | 50.38M | 38.02M | 29.09M | 21.32M | 19.70M | 19.84M | 19.84M |
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.37 per share a year ago.
ATTENTION Zymeworks Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ATTENTION ZYME SHAREHOLDERS: Investors who Lost Money on Zymeworks Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that...
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary platforms to...
ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that...
Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that...
Source: https://incomestatements.info
Category: Stock Reports